Literature DB >> 7631356

Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

R G Hart1, B S Boop, D C Anderson.   

Abstract

BACKGROUND: Intracranial hemorrhage is the most feared and lethal complication of oral anticoagulation. We review the frequency, predictors, and prognosis of this most common neurological complication of oral anticoagulation. SUMMARY OF REVIEW: Anticoagulation to conventional intensities increases the risk of intracranial hemorrhage 7- to 10-fold, to an absolute rate of nearly 1%/y for many stroke-prone patients. Most (70%) anticoagulant-related intracranial hemorrhages are intracerebral hematomas (approximately 60% are fatal); the bulk of the remainder are subdural hematomas. Predictors of anticoagulant-related intracerebral hematoma are advanced patient age, prior ischemic stroke, hypertension, and intensity of anticoagulation. In approximately half of anticoagulated patients with intracerebral hematoma the bleeding evolves slowly over 12 to 24 hours, and emergency reversal of anticoagulation is crucial.
CONCLUSION: Both patient factors and anticoagulation intensity importantly influence the rate of anticoagulation-related intracranial hemorrhage. Patient-related risk factors for this complication overlap with those for ischemic stroke. The risk/benefit equation of anticoagulation for elderly, stroke-prone patients is complex and differs from that for younger patients. The absolute rate reduction (not the relative risk reduction) of ischemic stroke by anticoagulation is the critical issue and must offset accentuation of often lethal brain hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631356     DOI: 10.1161/01.str.26.8.1471

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  105 in total

1.  Emergency case. Head injury in patients using warfarin.

Authors:  B Fleming
Journal:  Can Fam Physician       Date:  2001-04       Impact factor: 3.275

2.  Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.

Authors:  David L Brody; Venkatesh Aiyagari; Angela M Shackleford; Michael N Diringer
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.

Authors:  Michael Moussouttas
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 4.  More than one dilemma.

Authors:  Robert D Henderson; David G Walker; Ken Mitchell; Stephan J Read
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 5.  Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy?

Authors:  Mushtaq Wani; Emma Nga; Ranjini Navaratnasingham
Journal:  BMJ       Date:  2005-08-20

6.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 7.  Stroke prevention in atrial fibrillation: warfarin faces its challengers.

Authors:  Joseph L Blackshear; Fred Kusumoto
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

8.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

9.  Brain microhemorrhages detected on T2*-weighted gradient-echo MR images.

Authors:  Yoshito Tsushima; Jun Aoki; Keigo Endo
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

10.  Elevated International Normalized Ratio Is Associated With Ruptured Aneurysms.

Authors:  Anil Can; Victor M Castro; Dmitriy Dligach; Sean Finan; Sheng Yu; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.